A Phase 1 Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh CGRP Immunotherapy (UB-313) in Healthy Participants
Latest Information Update: 14 Mar 2025
At a glance
- Drugs UB 313 (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Vaxxinity
- 12 Mar 2025 Status changed from active, no longer recruiting to completed.
- 09 May 2023 According to a Vaxxinity media release, the company anticipates data readout from this study in this second quarter of 2023.
- 06 Mar 2023 Planned End Date changed from 1 Aug 2023 to 1 Oct 2023.